{"id":412660,"date":"2021-01-12T01:03:29","date_gmt":"2021-01-12T06:03:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=412660"},"modified":"2021-01-12T01:03:29","modified_gmt":"2021-01-12T06:03:29","slug":"addex-to-present-at-the-baader-helvea-swiss-equities-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/","title":{"rendered":"Addex to Present at the Baader Helvea Swiss Equities Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>Geneva, Switzerland, January 12, 2021<\/strong><br \/>\n        <strong>\u00a0&#8211; <\/strong>\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CIhmp7x-qIz7EYiMHtqR3anKfF_WtTWb7VGiA_xyqvgJmXPW65tv8LeudhbJBkgH0B_KVTXdVjqfMi14q9_OeYKz3dO35ION5imqAto1fFA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Addex Therapeutics<\/u><\/a>\u00a0Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer,\u00a0is scheduled to participate in the virtual <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9WbZwBf3700Kbk09g01W86D8V-w4LfGtDpdx-ziYOLRbgjNofm65QzZV_eKRFq9ys-KVUqAVCYIEgG7sHvLPmLf4ginmNPlpmSgnjjYOtGMs2kaFzohBg1qBo2Y9v86L_16QbBSScGrMT9XusRez-g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Baader Helvea Swiss Equities Conference<\/u><\/a> taking place on January 13 \u2013 January 15, 2021.<\/p>\n<p align=\"justify\">In the presentation, which will take place on January 13, 2021 at 14:50 &#8211; 15:30 CET, Mr Dyer will provide a corporate update and discuss recent developments. He will be available for virtual one-on-one meetings throughout the conference. <\/p>\n<p align=\"justify\">\n        <strong>About Addex Therapeutics:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CIhmp7x-qIz7EYiMHtqR3cQ5SdKFyAg0uwglnRigLZv-SHF19CiI4InZeOIYG8djWDIdtZpHsz-5Iz78PIusU_jPd3BMrxZmUmRyEBnK-5hPd4rnFhFHoesVJFjGOTnI\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n          <u>Addex Therapeutics\u00a0<\/u><br \/>\n        <\/a>is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional &#8220;orthosteric&#8221; small molecule or biological drugs. Addex&#8217;s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex&#8217;s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start \u00a0a pivotal registration clinical trial for Parkinson\u2019s disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also investigating dipraglurant&#8217;s therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021. Addex&#8217;s third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in H1 2021. Addex\u2019s GABAB\u00a0PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABA<sub>B<\/sub>\u00a0PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson\u2019s disease and mGlu3 PAM for neurodegenerative disorders.<strong>\u00a0<\/strong>Addex is listed on the SIX Swiss Exchange and NASDAQ Capital Market, and trades under the ticker symbol &#8220;ADXN&#8221;.<\/p>\n<p align=\"justify\">\n        <strong>Press Contacts:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;border-collapse:collapse\">\n<tr>\n<td style=\"width:2065px;text-align: justify;vertical-align: middle;vertical-align: top;text-align: justify;vertical-align: middle\">Tim Dyer<br \/>Chief Executive Officer<br \/>Telephone: +41 22 884 15 55<br \/>Email:\u00a0<a href=\"mailto:PR@addextherapeutics.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>PR@addextherapeutics.com<\/u><\/a><\/td>\n<td style=\"width:2085px;text-align: justify;vertical-align: middle;vertical-align: top;text-align: justify;vertical-align: middle\">Mike Sinclair<br \/>Partner, Halsin Partners<br \/>+44 (0)20 7318 2955<br \/><a href=\"mailto:msinclair@halsin.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>msinclair@halsin.com<\/u><\/a><\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>Forward Looking Statements:<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including in respect of the anticipated initiation of clinical trials. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release,\u00a0 are based on management&#8217;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled \u201cRisk Factors\u201d in Addex Therapeutics\u2019 Annual Report on Form 20-F for the year ended December 31, 2019, as filed with the SEC on April 27, 2020, the prospectus related to the global offering and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics\u2019 views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements. <\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDI4MiM0MDA4NTA3MzQjMjAwMjU4Ng==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/f3a93828-bb26-43ed-a301-deea33afd711\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Geneva, Switzerland, January 12, 2021 \u00a0&#8211; \u00a0Addex Therapeutics\u00a0Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer,\u00a0is scheduled to participate in the virtual Baader Helvea Swiss Equities Conference taking place on January 13 \u2013 January 15, 2021. In the presentation, which will take place on January 13, 2021 at 14:50 &#8211; 15:30 CET, Mr Dyer will provide a corporate update and discuss recent developments. He will be available for virtual one-on-one meetings throughout the conference. About Addex Therapeutics: Addex Therapeutics\u00a0 is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Addex to Present at the Baader Helvea Swiss Equities Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-412660","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Addex to Present at the Baader Helvea Swiss Equities Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Addex to Present at the Baader Helvea Swiss Equities Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Geneva, Switzerland, January 12, 2021 \u00a0&#8211; \u00a0Addex Therapeutics\u00a0Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer,\u00a0is scheduled to participate in the virtual Baader Helvea Swiss Equities Conference taking place on January 13 \u2013 January 15, 2021. In the presentation, which will take place on January 13, 2021 at 14:50 &#8211; 15:30 CET, Mr Dyer will provide a corporate update and discuss recent developments. He will be available for virtual one-on-one meetings throughout the conference. About Addex Therapeutics: Addex Therapeutics\u00a0 is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric &hellip; Continue reading &quot;Addex to Present at the Baader Helvea Swiss Equities Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-12T06:03:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDI4MiM0MDA4NTA3MzQjMjAwMjU4Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Addex to Present at the Baader Helvea Swiss Equities Conference\",\"datePublished\":\"2021-01-12T06:03:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\\\/\"},\"wordCount\":573,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1MDI4MiM0MDA4NTA3MzQjMjAwMjU4Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\\\/\",\"name\":\"Addex to Present at the Baader Helvea Swiss Equities Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1MDI4MiM0MDA4NTA3MzQjMjAwMjU4Ng==\",\"datePublished\":\"2021-01-12T06:03:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1MDI4MiM0MDA4NTA3MzQjMjAwMjU4Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1MDI4MiM0MDA4NTA3MzQjMjAwMjU4Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Addex to Present at the Baader Helvea Swiss Equities Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Addex to Present at the Baader Helvea Swiss Equities Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/","og_locale":"en_US","og_type":"article","og_title":"Addex to Present at the Baader Helvea Swiss Equities Conference - Market Newsdesk","og_description":"Geneva, Switzerland, January 12, 2021 \u00a0&#8211; \u00a0Addex Therapeutics\u00a0Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer,\u00a0is scheduled to participate in the virtual Baader Helvea Swiss Equities Conference taking place on January 13 \u2013 January 15, 2021. In the presentation, which will take place on January 13, 2021 at 14:50 &#8211; 15:30 CET, Mr Dyer will provide a corporate update and discuss recent developments. He will be available for virtual one-on-one meetings throughout the conference. About Addex Therapeutics: Addex Therapeutics\u00a0 is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric &hellip; Continue reading \"Addex to Present at the Baader Helvea Swiss Equities Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-12T06:03:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDI4MiM0MDA4NTA3MzQjMjAwMjU4Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Addex to Present at the Baader Helvea Swiss Equities Conference","datePublished":"2021-01-12T06:03:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/"},"wordCount":573,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDI4MiM0MDA4NTA3MzQjMjAwMjU4Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/","name":"Addex to Present at the Baader Helvea Swiss Equities Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDI4MiM0MDA4NTA3MzQjMjAwMjU4Ng==","datePublished":"2021-01-12T06:03:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDI4MiM0MDA4NTA3MzQjMjAwMjU4Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1MDI4MiM0MDA4NTA3MzQjMjAwMjU4Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/addex-to-present-at-the-baader-helvea-swiss-equities-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Addex to Present at the Baader Helvea Swiss Equities Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=412660"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412660\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=412660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=412660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=412660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}